KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2025)

Recursion Pharmaceuticals' Net Margin history spans 6 years, with the latest figure at 304.24% for Q4 2025.

  • For Q4 2025, Net Margin rose 363122.0% year-over-year to 304.24%; the TTM value through Dec 2025 reached 863.35%, down 7533.0%, while the annual FY2025 figure was 863.35%, 7533.0% down from the prior year.
  • Net Margin reached 304.24% in Q4 2025 per RXRX's latest filing, up from 3135.32% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 304.24% in Q4 2025 to a low of 3935.46% in Q4 2024.
  • Average Net Margin over 5 years is 1217.28%, with a median of 872.82% recorded in 2022.
  • Peak YoY movement for Net Margin: soared 2938181bps in 2021, then plummeted -308158bps in 2024.
  • A 5-year view of Net Margin shows it stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then plummeted by -91bps to 853.88% in 2023, then crashed by -361bps to 3935.46% in 2024, then soared by 92bps to 304.24% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Net Margin are 304.24% (Q4 2025), 3135.32% (Q3 2025), and 894.23% (Q2 2025).